For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Lixisenatide
Illustration for Lixisenatide

THE PEPSRADAR ENCYCLOPEDIA

Lixisenatide

Diabetes and cardiovascular outcomes

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Lixisenatide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (Soliqua 100/33) on DailyMed ↗

What is Lixisenatide?

Lixisenatide is a GLP-1 receptor agonist. ELIXA studied cardiovascular safety in people with type 2 diabetes who had recently experienced an acute coronary event.

Biological role or research focus

Diabetes and cardiovascular outcomes.

The finding supports cardiovascular safety within the trial’s prespecified framework. It does not establish cardiovascular benefit. Heart-failure hospitalization and mortality were not significantly different. Sanofi funded the trial.

Role reference: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

Class / identity
GLP-1 receptor agonist
Research focus
Diabetes and cardiovascular outcomes
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

Quick answers

Is Lixisenatide FDA approved?
Yes. Adlyxin (BLA 208471, approved 2016) and Soliqua (with insulin glargine, BLA 208673) for type 2 diabetes. Source ↗
Is Lixisenatide safe?
Lixisenatide is a GLP-1 drug; its current US label is the Soliqua combination with insulin glargine, which warns of low blood sugar, pancreatitis, serious allergic reactions and severe stomach side effects. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Lixisenatide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
Has the FDA taken action over Lixisenatide?
Yes. Our records list 1 FDA action naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research
StudyTypePopulation / model
ELIXA (2015)Human randomized trial6,068 people with type 2 diabetes and an acute coronary event in the preceding 180 days.
LIXIPARK · early Parkinson disease (2024)Human phase 2 randomized trial156 people diagnosed less than three years earlier, receiving stable symptomatic medication and without motor complications.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2015

ELIXA

Did cardiovascular events differ after a recent coronary event?

Population / model
6,068 people with type 2 diabetes and an acute coronary event in the preceding 180 days.
Study design
Randomized placebo-controlled cardiovascular-outcomes study; median follow-up 25 months.
Main finding
The primary cardiovascular composite occurred in 13.4% with lixisenatide and 13.2% with placebo: hazard ratio 1.02 (95% CI 0.89–1.17). Noninferiority was established; superiority was not.
Limits & context
The finding supports cardiovascular safety within the trial’s prespecified framework. It does not establish cardiovascular benefit. Heart-failure hospitalization and mortality were not significantly different. Sanofi funded the trial.

Source: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

Human phase 2 randomized trial · 2024

LIXIPARK · early Parkinson disease

Did motor-disability progression differ in early Parkinson disease?

Population / model
156 people diagnosed less than three years earlier, receiving stable symptomatic medication and without motor complications.
Study design
Double-blind placebo-controlled trial over 12 months, followed by a two-month washout. The primary motor-score endpoint was assessed in the on-medication state.
Main finding
MDS-UPDRS part III changed by −0.04 points with lixisenatide versus +3.04 with placebo; difference 3.08 points (95% CI 0.86–5.30). Nausea occurred in 46% and vomiting in 13% of lixisenatide recipients.
How to read it
This phase 2 motor-score result is a distinct question from ELIXA cardiovascular safety in diabetes.
Limits & context
Other secondary outcomes did not differ substantially. Larger and longer trials are needed; this is not proof of cure, prevention, or an established Parkinson indication.

Source: Meissner et al. · NEJM · LIXIPARK · 2024 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

64 registered studies name Lixisenatide as an intervention; 3 are recruiting or under way, 1 has not started recruiting yet, 53 completed and 7 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
NCT06716424 · Sanofi
CompletedPhase 42025-01-06105
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235 · Shanghai Zhongshan Hospital
RecruitingPhase 42025-12-131316
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
NCT06671587 · Sanofi
RecruitingPhase 42024-12-10678
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
NCT07173712 · Yanbing Li
Not yet recruitingPhase 42026-03-15324
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
NCT03439943 · University Hospital, Toulouse
CompletedPhase 22018-06-13156
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
NCT05413369 · Sanofi
CompletedPhase 32022-07-07582
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
NCT07117240 · Medical University of Warsaw
Enrolling by invitationPhase 42025-07-10100
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
NCT05114590 · Sanofi
CompletedPhase 42022-01-27124

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 64 listed studies.

Search additional PubMed records ↗

Risks & interactions

Lixisenatide is a GLP-1 drug; its current US label is the Soliqua combination with insulin glargine, which warns of low blood sugar, pancreatitis, serious allergic reactions and severe stomach side effects.

Human safety data: FDA label

The FDA label summarized here is for Soliqua, which combines lixisenatide with insulin glargine. Some warnings, such as low blood sugar and low potassium, come mainly from the insulin part; lixisenatide's own warnings include pancreatitis, allergic reactions and stomach side effects.

Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicinesKidney problems

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • During an episode of low blood sugar
  • Serious allergy to lixisenatide, insulin glargine or any ingredient
  • Severe gastroparesis (very slow stomach emptying): not recommended
  • End-stage kidney disease: not recommended

Interactions

  • Other diabetes medicines and many common drugs: can push blood sugar too low or too high
  • Beta-blockers, clonidine, guanethidine, reserpine: can hide the warning signs of low blood sugar
  • Oral medicines such as birth control pills, antibiotics and acetaminophen: slowed stomach emptying can change how they are absorbed
  • Other GLP-1 receptor agonists: should not be combined
  • Pioglitazone and similar PPAR-gamma drugs: fluid retention and heart failure risk

Serious risks

  • Severe allergic reactions, including anaphylaxis and angioedema
  • Acute pancreatitis, including fatal cases with GLP-1 drugs
  • Severe or life-threatening low blood sugar
  • Kidney injury from dehydration after vomiting or diarrhea
  • Low potassium, which can be life-threatening
  • Gallbladder disease, and inhaling stomach contents during anesthesia or deep sedation

Common side effects

  • nausea
  • diarrhea
  • low blood sugar
  • stuffy nose and sore throat
  • upper respiratory infections
  • headache

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Soliqua (insulin glargine and lixisenatide) prescribing information ↗

What the featured evidence can tell us

Read the product label for complete gastrointestinal, glucose-related, kidney, and interaction precautions. The ELIXA comparison cannot establish that all GLP-1 products share the same cardiovascular effect.

Source: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

Identity, route, and evidence limits

The finding supports cardiovascular safety within the trial’s prespecified framework. It does not establish cardiovascular benefit. Heart-failure hospitalization and mortality were not significantly different. Sanofi funded the trial.

Source: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

Regulatory status

U.S. FDA approval
Approved
Adlyxin (BLA 208471, approved 2016) and Soliqua (with insulin glargine, BLA 208673) for type 2 diabetes; Drugs@FDA lists both as prescription products. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

FDA actions

  • FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source

Other notes

  • Lixisenatide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical context & research status

This profile focuses on cardiovascular outcomes in a defined diabetes population. Product indications and precautions depend on the current local prescribing information.

Source: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. This drug is still investigational and is not approved for sale. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).

How Lixisenatide works

GLP-1 receptor agonism is an incretin approach to glucose regulation. A glucose-lowering mechanism does not by itself establish fewer heart attacks or longer survival; those outcomes require clinical trials.

Source: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

Molecular structure

Lixisenatide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
3D model not yet validated2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 90472060 ↗

Questions worth asking

  • Is noninferiority the same as a cardiovascular benefit?
  • What population, comparator, and route were actually studied?
  • The finding supports cardiovascular safety within the trial’s prespecified framework. It does not establish cardiovascular benefit. Heart-failure hospitalization and mortality were not significantly different. Sanofi funded the trial.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Is noninferiority the same as a cardiovascular benefit?

No. Noninferiority tests whether an unacceptable increase can be excluded within a specified margin. It is not proof that events were reduced.

Source: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

Does this page establish a supplier’s product quality?

No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.

Source: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · 2015 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Lixisenatide

Download illustration ↓Source record ↗
Lixisenatide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.